In This Section

Spotlight on Clinical Trials

Clinical Trials Abstract Submission DeadlineMonday, January 11, 2021, 12 p.m. U.S. ET

Submit Your Clinical Trials Abstracts to the AACR Annual Meeting 2021

Become a part of our growing clinical research program at the Annual Meeting and help us showcase how discovery science continues to transform the lives of cancer patients. 

Why You Should Submit
  • Numerous and unique oral presentation opportunities
    • Four Clinical Trials Plenary Sessions offering companion presentations explaining the science behind the presented trials (featuring 16 trials total)
    • Three Clinical Trials Minisymposia (featuring 21 trials total)
  • Poster presentations (enhanced e-Posters with opportunities for engagement)
  • Potential national media coverage through the extensive AACR press program
  • Opportunities to simultaneously present your work and publish a manuscript in a high-impact AACR journal
    • Indicate your intention to submit a manuscript during the abstract submission process.
    • Contact [email protected] with any questions.
  • No restrictions on presenters as long as the presentation is CME-compliant
What to Submit
  • Any phase (I, II, III, or any combination) abstract from national or international clinical trials
    • Biomarker studies:
      1. If the abstract describes a predefined biomarker analysis that was part of the original trial design and trial data will be reported, then it may be submitted to a clinical trials category.   
      2. If the biomarker analysis was not part of the original trial design or was performed post hoc, then the abstract should be submitted to a Clinical Research category (CL11 Biomarkers) for the November 19, 2020, deadline (or as a late-breaking Clinical Research abstract on January 11, 2021 if the study is not complete by November 19, 2020). 
  • Promising ongoing trials or unique trial designs that have not yet yielded results to the Clinical Trials in Progress category (CT08) (Note that placeholder abstracts are not permitted for Trials in Progress.)  
  • Encore presentations
  • COVID-19 and cancer clinical trials to the COVID-19 and Cancer (COVID06) or Clinical Trials for COVID-19 (CT07) categories.
When to Submit
  • Submit your completed or placeholder abstract(s) by the January 11, 2021 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 11, 2020 deadline.  
  • Final results and conclusions for placeholder abstracts are due by February 4, 2021.  
Clinical Trials (Including Combination Trials) Abstract Categories 
  • CT01 Phase I Adult Clinical Trials  
  • CT02 Phase II Adult Clinical Trials 
  • CT03 Phase III Adult Clinical Trials 
  • CT04 Phase I, II, or III Clinical Trials in Pediatric Cancer 
  • CT05 Phase I, II, or III Clinical Trials in the Elderly 
  • CT06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations 
  • CT07 Clinical Trials for COVID-19   
    • Phase I Clinical Trials
    • Phase II Clinical Trials
    • Phase III Clinical Trials
    • Phase IV, Observational, and Expanded Access Clinical Trials
    • Clinical trials in progress
  • CT08 Clinical Trials in Progress 
  • Phase I Clinical Trials 
  • Phase II Clinical Trials 
  • Phase III Clinical Trials 
Placeholder Abstract Categories 
  • PL01 Phase I Adult Clinical Trials 
  • PL02 Phase II Adult Clinical Trials 
  • PL03 Phase III Adult Clinical Trials 
  • PL04 Phase I, II, or III Clinical Trials in Pediatric Cancer 
  • PL05 Phase I, II, or III Clinical Trials in the Elderly 
  • PL06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations 
  • PL07 Clinical Trials for COVID-19
    • Phase I Clinical Trials
    • Phase II Clinical Trials
    • Phase III Clinical Trials
    • Phase IV, Observational, and Expanded Access Clinical Trials
    • Clinical trials in progress